1. Name and Address of Reporting Person
MORNEAU MICHAEL

C/O VIKING THERAPEUTICS, INC.
12340 EL CAMINO REAL, SUITE 250
SAN DIEGO, CA 92130

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [VKTX]

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
Director
X 10% Owner
Officer (give title below)
VP, Finance and Administration
Other (specify below)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Code</th>
<th>Amount</th>
<th>(A) or (D)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>7,500</td>
<td>07/31/2020(1)</td>
<td>07/31/2029</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. 1/3 of the shares subject to the option will vest on each anniversary of the grant date.

Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.